Effectiveness and safety of Abciximab after failed thrombolytic therapy

被引：17

作者：

Cantor, WJ ^{[1
]}

Kaplan, AL

Velianou, JL

Sketch, MH

Barsness, GW

Berger, PB

Ohman, EM

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27710 USA

[2] Mayo Clin, Rochester, MN USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2001年 / 87卷 / 04期

关键词：

D O I：

10.1016/S0002-9149(00)01398-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Among 214 patients treated with abciximab within 24 hours of full-dose thrombolytic therapy, major bleeding occurred in 50 patients (23%; 95% confidence interval [Cl] 18% to 30%) and intracranial hemorrhage occurred in 3 patients (1.4%; 95% Cl 0.3% to 4%). The independent multivariate predictors of major bleeding were age (odds ratio [OR] 1.53/10 years, 95% Cl 1.05 to 2.21, p = 0.03), time from thrombolytic to abciximab (OR 0.91/hour, 95% Cl 0.83 to 0.99, p = 0.03), and intra-aortic balloon pump insertion (OR 4.42, 95% Cl 2.00 to 9.72, p = 0.0002).

引用

页码：439 / +

页数：5

共 18 条

[1] BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [J].

AGUIRRE, FV ;

TOPOL, EJ ;

FERGUSON, JJ ;

ANDERSON, K ;

BLANKENSHIP, JC ;

HEUSER, RR ;

SIGMON, K ;

TAYLOR, M ;

GOTTLIEB, R ;

HANOVICH, G ;

ROSENBERG, M ;

DONOHUE, TJ ;

WEISMAN, HF ;

CALIFF, RM .

CIRCULATION, 1995, 91 (12) :2882-2890

[2] Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction [J].

Berkowitz, SD ;

Granger, CB ;

Peiper, KS ;

Lee, KL ;

Gore, JM ;

Simoons, M ;

Armstrong, PW ;

Topol, EJ ;

Califf, RM .

CIRCULATION, 1997, 95 (11) :2508-2516

[3] HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL [J].

BOVILL, EG ;

TERRIN, ML ;

STUMP, DC ;

BERKE, AD ;

FREDERICK, M ;

COLLEN, D ;

FEIT, F ;

GORE, JM ;

HILLIS, LD ;

LAMBREW, CT ;

LEIBOFF, R ;

MANN, KG ;

MARKIS, JE ;

PRATT, CM ;

SHARKEY, SW ;

SOPKO, G ;

TRACY, RP ;

CHESEBRO, JH .

ANNALS OF INTERNAL MEDICINE, 1991, 115 (04) :256-265

[4] Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction [J].

Brener, SJ ;

Barr, LA ;

Burchenal, JEB ;

Katz, S ;

George, BS ;

Jones, AA ;

Cohen, ED ;

Gainey, PC ;

White, HJ ;

Cheek, HB ;

Moses, JW ;

Moliterno, DJ ;

Effron, MB ;

Topol, EJ .

CIRCULATION, 1998, 98 (08) :734-741

[5] HEMORRHAGIC COMPLICATIONS ASSOCIATED WITH THE USE OF INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR IN TREATMENT OF ACUTE MYOCARDIAL-INFARCTION [J].

CALIFF, RM ;

TOPOL, EJ ;

GEORGE, BS ;

BOSWICK, JM ;

ABBOTTSMITH, C ;

SIGMON, KN ;

CANDELA, R ;

MASEK, R ;

KEREIAKES, D ;

ONEILL, WW ;

STACK, RS ;

STUMP, D .

AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) :353-359

[6] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[7] CHARACTERISTICS AND OUTCOME OF PATIENTS IN WHOM REPERFUSION WITH INTRAVENOUS TISSUE-TYPE PLASMINOGEN-ACTIVATOR FAILS - RESULTS OF THE THROMBOLYSIS AND ANGIOPLASTY IN MYOCARDIAL-INFARCTION (TAMI) I-TRIAL [J].

CALIFF, RM ;

TOPOL, EJ ;

GEORGE, BS ;

BOSWICK, JM ;

LEE, KL ;

STUMP, D ;

DILLON, J ;

ABBOTTSMITH, C ;

CANDELA, RJ ;

KEREIAKES, DJ ;

ONEILL, WW ;

STACK, RS .

CIRCULATION, 1988, 77 (05) :1090-1099

[8] Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction [J].

Lefkovits, J ;

Ivanhoe, RJ ;

Califf, RM ;

Bergelson, BA ;

Anderson, KM ;

Stoner, GL ;

Weisman, HF ;

Topol, EJ .

AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (12) :1045-1051

[9] Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial) [J].

Miller, JM ;

Smalling, R ;

Ohman, EM ;

Bode, C ;

Betriu, A ;

Kleiman, NS ;

Schildcrout, JS ;

Bastos, E ;

Topol, EJ ;

Califf, RM .

AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (07) :779-784

[10]

Ohman EM, 1998, CIRCULATION, V98, P504

← 1 2 →